Protagonist Therapeutics, Inc.
PTGX
株式のランク
#2189
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
株価
$139.43
時価総額
$9.02B
変化（1日）
0.98%
変化（1年）
89.70%
国
US
取引 Protagonist Therapeutics, Inc. (PTGX)
カテゴリー
Healthcare
Protagonist Therapeutics, Inc.（PTGX）の株価履歴
終値の最高値: $138.64 （2026-10-01）
終値の最安値: $11.34 （2016-08-01）
終値の最安値: $11.34 （2016-08-01）
Protagonist Therapeutics, Inc. の株価履歴（2016 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | 21.88% |
| 2025 | 119.26% |
| 2024 | 92.93% |
| 2023 | 131.51% |
| 2022 | -72.05% |
| 2021 | 46.48% |
| 2020 | 203.82% |
| 2019 | 9.00% |
| 2018 | -65.01% |
| 2017 | -15.57% |
| 2016 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $533.96 | 25.21% |
US
|
|
| $232.80 | 767.04% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $882.27 | 8.36% |
NL
|
|
| $290.30 | 1.99% |
BE
|
